Weigao Group

Weigao Group (威高集团) is a major Chinese healthcare company specializing in medical consumables and devices. Founded in 1988 in Weihai, Shandong Province, the company has grown into one of China's largest suppliers of disposable medical products, including syringes, surgical gloves, wound dressings, infusion sets, and blood purification equipment. Its product portfolio serves hospitals, clinics, and healthcare providers across China and international markets. The group operates through several subsidiaries and is publicly listed on the Hong Kong Stock Exchange under the ticker 1066.HK. Weigao is known for its extensive distribution network in China and has been expanding its global footprint through exports and partnerships. The company invests significantly in research and development, focusing on high-value medical devices and consumables. Weigao's brand is associated with reliable, high-quality medical supplies, and it holds numerous certifications for international standards. Its product lines cover infusion therapy, orthopedic devices, blood purification, and minimally invasive surgical instruments. The company's mission is to improve healthcare accessibility and quality through innovative medical solutions. With decades of experience, Weigao Group has become a key player in China's healthcare industry, contributing to the domestic supply of essential medical consumables and advancing medical technology. It remains committed to expanding its product offerings and global reach.

Weigao Group was founded in 1988 in Weihai, Shandong Province, China, initially producing disposable medical consumables. Over the years, it expanded its product lines to include syringes, surgical gloves, wound dressings, and infusion sets. In the 1990s and 2000s, Weigao grew rapidly, capitalizing on China's healthcare reforms and increasing demand for medical supplies. The company established a strong distribution network across China and began exporting to international markets. In 2004, Weigao's subsidiary, Shandong Weigao Group Medical Polymer Company Limited, was listed on the Hong Kong Stock Exchange (stock code: 1066.HK), providing capital for further expansion. The group diversified into high-value segments such as blood purification, orthopedic implants, and minimally invasive surgical devices. Through acquisitions and R&D investments, Weigao strengthened its technological capabilities and market position. By the 2010s, Weigao had become one of China's largest medical device companies, with a broad portfolio and significant market share in consumables. It continued to invest in innovation, establishing research centers and collaborating with international partners. The company also focused on quality management, obtaining certifications such as ISO 13485 and CE marks for many products. In recent years, Weigao has accelerated its globalization strategy, targeting emerging markets and developed countries. It remains a key player in China's healthcare industry, contributing to the supply of essential medical products and advancing domestic medical technology.

• 2004

  Subsidiary listed on Hong Kong Stock Exchange (1066.HK)

• 1988

  Founded in Weihai, Shandong, China

• Disposable syringes

• Surgical gloves

• Wound dressings

• Infusion sets

• Blood purification equipment

• Orthopedic devices

• 2020

  Commercial bribery cases involving employee and agents

  Weigao Holdings salesperson Ci Mou-long was sentenced to two years and six months for bribery; in 2026 the company publicly apologized and admitted gaps in personnel controls; in another case, an agent gave a 30% cash rebate on orthopedic steel plates and bribed hospital personnel more than RMB 2.38 million. The employee was sentenced; the company apologized and rectified.

  Source

Read more

• Unconfirmed

  Weigao Blood Purification to acquire Weigao PRP for RMB 8.511 billion[5]威高血净拟85.11亿元收购威高普瑞100%股权nbd.com.cn

  Weigao Blood Purification released a draft report on issuing shares to acquire assets and related-party transactions, planning to issue shares to buy 100% of Weigao PRP held by Weigao Co., Weihai Shengxi and Weihai Ruiming for RMB 8.511 billion. Weigao PRP develops, produces and sells pharmaceutical packaging such as prefilled drug delivery systems and automatic safety drug delivery systems.

Read more

1. 1Weigao Group Official Websiteweigaogroup.com
2. 2Commercial bribery cases involving employee and agentsfinance.sina.com.cn
3. 3Commercial bribery cases involving employee and agentssd.ifeng.com
4. 4Commercial bribery cases involving employee and agentsjiemian.com
5. 5威高血净拟85.11亿元收购威高普瑞100%股权nbd.com.cn